Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

5-LO inhibitor not effective as monotherapy in active ulcerative colitis

April 7, 1997

Positive phase III results reported for Centocor's Crohn's disease treatment

April 7, 1997

Court rules in favor of Novopharm regarding generic ranitidine product

April 7, 1997

Budesonide cleared in Canada for Crohn's disease

April 4, 1997

Transdermal nicotine associated with clinical improvement in ulcerative colitis

April 2, 1997

Gilead's GS-840 enters phase II for chronic hepatitis B treatment

April 1, 1997

Extended treatment with Intron A for hepatitis C cleared by FDA

April 1, 1997

Shaman commences phase II trials of Provir in AIDS-related diarrhea

April 1, 1997

Kaken prepares broad-spectrum antiulcer agent

March 27, 1997

Axcan receives approvable letter for URSO from FDA

March 26, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...